Skip to main content
Equibles

SMNR · Semnur Pharmaceuticals, Inc.

Track SMNR — free

Use SMNR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SMNR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.45 -0.12 (-21.05%) At close · Oct 2
Rebalance outlook locked
Going-concern doubt — flagged Aug 10, 2026

Substantial doubt about the company's ability to continue as a going concern.

“As a result, management has concluded that the aforementioned conditions, among other things, raise substantial doubt about the Company's ability to continue as a going concern for one year after the date the condensed consolidated financial statements are issued.”
View the 10-Q filed Aug 10, 2026
Market Cap
$137.90M
Shares
230.21M
Volume · Oct 2 3553 Avg daily vol (3M) 10.01K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.45 Open$0.45 Day$0.45–0.58 Available close range$0.35–23.00 Avg vol 30d6K Short int92K · 0.0% float · 10.9d Short vol13% DataSep 2025–Oct 2026 Filing10-Q · Aug 10

The closing range uses available history since Nov 10, 2025; less than a full year is stored.

Up next

Latest filing: 10-Q
filed Aug 10, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-95.0%
Trailing year
Short interest
0.0%
Latest settlement · 10.9 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 15.3 · calm Equity put/call 0.58
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 50-day avg −29%
below
RSI (14) 41
neutral
MACD trend Positive
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −18%
trailing
YTD return −98%
this year
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+2 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.04% of float · ▲ +0.0% MoM · 10.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
2 holders — near 4-yr low, contrarian setup
Squeeze score 34
low risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 420%
annualized · 1-yr
Max drawdown −98%
past year
ATR 32.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 50-day avg
−29% Bearish
RSI (14)
41 Neutral
MACD trend
Positive Bullish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+2 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.04% of float · ▲ +0.0% MoM · 10.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
2 holders — near 4-yr low, contrarian setup
Price context
position in its available closing range
Range low $0 Now $0 · 0% Range high $23
vs 50-day avg -29%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SMNR
Semnur Pharmaceuticals, Inc.
this stock
$137.90M -98.0% — — 0.0%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +11.3% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -4.8% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $79.40B +544.3% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
2
% held
0.0%
Net QoQ
+146 sh
Top holder
GAMMA Investing LLC
Held Float
View
Held by Funds
Fund positions
7
View
Short & Settlement
Short Interest Rising
Shares short
92.0K
Days to cover
10.9d
Change
+2 sh
View
Short Volume
Short vol %
13%
As of
Oct 5, 2026
Short Total
View
Fails to Deliver
FTD shares
810
Value
$405
As of
Sep 11, 2026
View
Off-Exchange
Off-exchange %
99.9%
Week of
Aug 31, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-160.4M
EPS diluted
$-0.78
View
Filings
SEC Filings
Latest
10-Q
Filed
Aug 10, 2026
This year
8
View

Performance

5D 20D 120D MTD YTD
SMNR -24.9% -18.2% — -19.1% -98.0%
SPY -0.2% -0.5% +12.2% +0.9% +12.9%
vs SPY -24.7% -17.7% — -20.0% -110.9%
Key facts CIK 1913577 CUSIP 81686G105 Visit website Investor relations